Increased tumor latency in xenograft models, and ultimately the response in human clinical trials showing prolonged time to progression may be the more accurate way to assess the therapeutic potential of mutant IDH inhibition and similarly directed novel therapies. This evidence concerns the gene IDH1 and neoplasm.